Depression

The novel oral agent is administered once daily for 14 days and has demonstrated rapid and sustained improvement in symptoms across trials.

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, comment on the impact of various classes of MDD treatments on time to achieve goals and/or response.

Carmen Kosicek, MSN, PMHNP-BC, leads a discussion on the level of satisfaction for both patients and providers with currently available MDD treatment options, barriers to access, and the impact of residual symptoms on a patient’s quality of life.

Mental health issues among health care professionals have always been normal; now that we can acknowledge them, we must, says a family physician and wellness advocate.

Experts in psychiatry share their treatment approaches for the management of episodic and chronic MDD.

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, review currently available treatment options for the management of MDD and criteria used for treatment selection.

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, provide advice regarding monitoring for adverse events and compliance with different classes of MDD treatment and review suggestions for follow-up and special patient populations.

Experts in psychiatry share their thoughts on the perception of MDD within the healthcare community and the implications of this condition being viewed as chronic vs episodic.

Carmen Kosicek, MSN, PMHNP-BC, and Charles Montano, MD, comment on the interplay between depression and other comorbid psychiatric and medical health conditions as well as the economic impact of MDD.

Charles Montano, MD; Carmen Kosicek, MSN, PMHNP-BC; and Gus Alva, MD, DFAPA, review the impact of the duration of MDD episodes and goals of managing episode recurrences.

While 60% of US psychologists have no openings for new patients, demand for treatment continues to rise, especially among adolescents and health care workers.

Not every physician has to be a mental health expert to assist their colleagues, staff, and patients in improving their mental well-being. Just start the conversation.

For the first time, the task force recommended screening children aged 8 and older for anxiety in primary care settings.

There was no change in physician burnout in the past year and it remains significantly higher than pre-pandemic times, according to a new nationwide survey.

Novel NMDA receptor antagonist approved for the treatment of major depressive disorder, first topical PDE4i approved for plaque psoriasis, and more.

Telehealth continues to support continuity of care and to increase access to and willingness to use the health care system, according to survey authors.

The numbers drive up concern but do not provide context for this very complex issue, according to the American Foundation for Suicide Prevention.

The percentage of adults who received any mental health treatment increased, women were more likely than men to receive treatment, and 3 more key findings.

USPSTF's draft statement is the first it has issued recommending primary care screening for adults younger than 65 who do not have signs or symptoms of anxiety or depression.

The dextromethorphan HBr-bupropion HCI combination uses the first new oral MOA in 6 decades and is labeled to improve depressive symptoms starting at 1 week.

The ACP and AAFP along with 6 other professional groups say the current system is failing US mental health needs and it's time to make changes.

US CV health is well below ideal, with 80% of adults scoring as only low or moderate in the first published study using AHA's new Life's Essential 8 algorithm.

A literature review comprising ~1.3 million patients infected with SARS-CoV-2 reveals women are 22% more likely vs men to develop long COVID, yet treatment is no different.

Understanding the interplay between obesity and depression in children is key for clinicians to best advise this patient population. An overview, here.

Most adults continue to mask indoors in public places and still limit their pre-pandemic activities.